Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

+68 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Alliance for Clinical Trials in Oncology

No Placebo Group

Trial Summary

What is the purpose of this trial?

RATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment. PURPOSE: Diagnostic study to determine the genetic markers in patients who have aggressive non-Hodgkin's lymphoma.

Eligibility Criteria

Inclusion Criteria

Histologically proven aggressive non-Hodgkin's lymphoma and registered to front-line CALGB protocols (e.g, CLB-59903, 59909, 10002, and 50103)

Diffuse small cleaved cell lymphoma

Diffuse mixed small and large cell lymphoma

See 5 more

Treatment Details

Interventions

Comparative Genomic Hybridization (Genetic)
Cytogenetic Analysis (Genetic)
Fluorescence in situ hybridization (Genetic)
Gene Rearrangement Analysis (Genetic)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Group 1Experimental Treatment4 Interventions

Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission. Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.